AstraZeneca’s New Oral GLP-1 Medication Shows Promise for Weight Loss and Blood Sugar Control

AstraZeneca has recently announced encouraging results from a phase 2b clinical trial of its new oral medication, elecoglipron, which targets type 2 diabetes. The trial revealed that participants experienced an average weight loss of 10.5% over the course of 26 weeks, alongside significant reductions in blood sugar levels.

The findings were presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans and published in *The Lancet*. In the study, 406 adults diagnosed with type 2 diabetes took part, with results indicating that nearly 90% of those receiving elecoglipron achieved their target HbA1c levels—a standard measure for average blood glucose levels—compared to just 25% in the placebo group.

Elecoglipron is part of a new wave of GLP-1 medications that come in oral form, offering an alternative to existing injectables like Ozempic and Wegovy. The first oral GLP-1 medication, Rybelsus, was developed by Novo Nordisk and approved by the FDA in 2019 for managing type 2 diabetes. The recent approval of other oral options like Wegovy and Foundayo indicates a growing trend towards pill-based treatments for weight management and diabetes.

Experts outside of AstraZeneca’s trial have expressed optimism about the potential of elecoglipron. Dr. Pouya Shafipour, a physician specializing in family and obesity medicine, called the results “exciting,” highlighting the significance of another non-injectable option in the market. Dr. Marilyn Tan, an endocrinologist and professor, echoed these sentiments, noting the expanding market for GLP-1 medications and the potential for elecoglipron to gain FDA approval if phase 3 trials are successful.

The SOLSTICE trial, funded by AstraZeneca, explored various dosing strategies for elecoglipron over a 26-week period. Researchers noted that 72% of treatment participants achieved at least a 5% reduction in weight, with an average loss of 10.5%. The safety profile of elecoglipron was consistent with that of other GLP-1 medications.

While the results are promising, both Dr. Shafipour and Dr. Tan stress the importance of lifestyle changes in conjunction with medication. GLP-1 drugs are intended to complement a healthy lifestyle, including regular exercise and a balanced diet, rather than serve as a quick fix.

Type 2 diabetes affects approximately 40 million people in the U.S., with many cases remaining undiagnosed. The condition is characterized by high blood sugar levels due to the body’s inadequate response to insulin. Symptoms may include constant hunger, excessive thirst, fatigue, and blurry vision.

The emergence of oral GLP-1 medications like elecoglipron represents a significant advancement in diabetes and obesity treatment, offering hope for improved management of these chronic conditions. However, healthcare providers advise patients to engage in informed discussions about the most suitable treatment options, emphasizing the necessity for a holistic approach to health management.